H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Alnylam Pharmaceuticals to $405 from $415 and keeps a Buy rating on the shares. The Roche collaboration increases the ocmpany’s financial and strategic flexibility, the analyst tells investors in a research note. The firm’s updated model reflects the economics of the Roche collaboration on zilebesiran. It now values zilebesiran at $5 per share verses $15 prior.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
- Alnylam enters pact with Roche to develop, commercialize zilebesiran
- Alnylam announces publication of Zilebesiran results in NEJM
- BridgeBio data in ATTR-CM ‘bodes well’ for Alnylam, says BofA
- BridgeBio data positive for Alnylam and Ionis, says Citi
- Alnylam announces updated interim results from ALN-APP study